Clinical Trials Arena on MSN

Acesion begins patient enrolment in AP31969 Phase II AF study

The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Acesion Pharma starts Phase 2 trial of AP31969 in patients with atrial fibrillation

Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering treatments for atrial fibrillation ("AF"), the most common cardiac arrhythmia, today announces enrolment of the first patients ...

HUYABIO International Presents Positive Clinical Results from HBI-3000, a Novel Multi-ion Channel Blocker for Acute Atrial Fibrillation

HUYABIO International today announced favorable Phase 1 clinical data for HBI-3000, a novel bioinspired investigational drug with promising antiarrhythmic properties, excellent tolerability and a ...
ahajournals.org

Drug Interactions Affecting Oral Anticoagulant Use

Oral anticoagulants (OACs) are medications commonly used in patients with atrial fibrillation and other cardiovascular conditions. Both warfarin and direct oral anticoagulants are susceptible to ...
IEEE

The Effect of Medication on P-wave Beat-to-Beat Variability in Atrial Fibrillation during Sinus Rhythm

Abstract: Atrial Fibrillation (AF) is the most common cardiac arrhythmia, and its progressive nature is associated with gradual atrial remodeling. The P-wave in the surface Electrocardiogram (ECG) ...